Yin Xiangrui, Xiong Wei, Wang You, Tang Wei, Xi Wang, Qian Shengqiang, Guo Yu
Department of Urology, Chongqing Hospital of Traditional Chinese Medicine.
Department of Urology, First Affiliated Hospital, Medical University of Chongqing, Chongqing, China.
Medicine (Baltimore). 2018 Sep;97(39):e11910. doi: 10.1097/MD.0000000000011910.
Human cytochrome P450 (CYP) is an enzyme responsible for the metabolic activation of many carcinogens, including nitrosamines. CYP2E1 represents a major CYP isoform and is expressed in the human urothelial cells. Recent studies have investigated the association of CYP2E1 gene polymorphisms with bladder cancer risk but have shown contradictory results. Hence, we performed a systematic literature review and meta-analysis to assess the association between CYP2E1 gene polymorphisms and bladder cancer.
Systematic literature searches were conducted with PubMed, Excerpt Medica Database, Science Direct/Elsevier, China National Knowledge Infrastructure, and the Cochrane Library up to January 2018 for studies that involved the association of CYP2E1 gene polymorphisms with bladder cancer risk. A meta-analysis was performed with Review Manager and Stata software. Combined odds ratios (ORs) were identified with 95% confidence intervals (CIs) in a random or fixed effects model.
The protocol was approved by the institutional review board of each study center. Written informed consent will be obtained from all patients before registration, in accordance with the Declaration of Helsinki.
Eight studies were identified, including 1733 cases of bladder cancer and 1814 normal controls. Our results illustrated that there are significant associations between CYP2E1 gene polymorphisms and bladder cancer in all genetic models (P < .05). The combined ORs and 95% CIs were as follows for each model: additive model [OR 0.56; 95% CI (0.38-0.82)]; dominant model [OR 0.79; 95% CI (0.67-0.93)]; recessive model [OR 0.61; 95% CI (0.41-0.89)]; codominant model [OR 0.80; 95% CI (0.67-0.96)]; allele model [OR 0.75; 95% CI (0.59-0.95)]. A subgroup study showed that there are also significant associations between CYP2E1 gene polymorphisms and bladder cancer in Asian people. However, there are no significant associations between CYP2E1 gene polymorphisms and bladder cancer in Caucasian populations.
The present study provides evidence for an association between CYP2E1 gene polymorphisms and bladder cancer progression, and suggests that CYP2E1 gene polymorphisms might be a protective factor against bladder cancer in Asian people. However, studies with larger sample sizes are needed to confirm the correlation between CYP2E1 gene polymorphisms and bladder cancer.
人类细胞色素P450(CYP)是一种负责多种致癌物代谢活化的酶,包括亚硝胺。CYP2E1是主要的CYP同工型,在人尿路上皮细胞中表达。最近的研究调查了CYP2E1基因多态性与膀胱癌风险之间的关联,但结果相互矛盾。因此,我们进行了一项系统的文献综述和荟萃分析,以评估CYP2E1基因多态性与膀胱癌之间的关联。
截至2018年1月,通过PubMed、医学文摘数据库、科学Direct/爱思唯尔、中国知网和考克兰图书馆进行系统的文献检索,以查找涉及CYP2E1基因多态性与膀胱癌风险关联的研究。使用Review Manager和Stata软件进行荟萃分析。在随机或固定效应模型中确定合并比值比(OR)及其95%置信区间(CI)。
该方案已获得每个研究中心机构审查委员会的批准。根据《赫尔辛基宣言》,将在所有患者登记前获得书面知情同意。
共纳入8项研究,包括1733例膀胱癌患者和1814例正常对照。我们的结果表明,在所有遗传模型中,CYP2E1基因多态性与膀胱癌之间均存在显著关联(P<0.05)。各模型的合并OR及其95%CI如下:加性模型[OR 0.56;95%CI(0.38 - 0.82)];显性模型[OR 0.79;95%CI(0.67 - 0.93)];隐性模型[OR 0.61;95%CI(0.41 - 0.89)];共显性模型[OR 0.80;95%CI(0.67 - 0.96)];等位基因模型[OR 0.75;95%CI(0.59 - 0.95)]。亚组研究表明,亚洲人群中CYP2E1基因多态性与膀胱癌之间也存在显著关联。然而,在白种人群中,CYP2E1基因多态性与膀胱癌之间无显著关联。
本研究为CYP2E1基因多态性与膀胱癌进展之间的关联提供了证据,并表明CYP2E1基因多态性可能是亚洲人群预防膀胱癌的一个保护因素。然而,需要更大样本量的研究来证实CYP2E1基因多态性与膀胱癌之间的相关性。